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Ciproﬂoxacin, a broad-spectrum antimicrobial agent belonging to the ﬂuoroquinolone family, is pre-
scribed off-label in infants less than one year of age. Ciproﬂoxacin is included in the European Medicines
Agency priority list of off-patent medicinal products requiring evaluation in neonates. This evaluation is
undergoing within the TINN (Treat Infections in Neonates) FP7 EU project. As part of the TINN project,
the present preclinical study was designed to assess the potential adverse effects of Ciproﬂoxacin on
neurodevelopment, liver and joints in mice. Newborn mice received subcutaneous Ciproﬂoxacin at 10, 30
and 100 mg/kg/day from 2 to 12 postnatal days. Peak plasma levels of Ciproﬂoxacin were in the range of
levels measured in human neonates. We examined vital functions in vivo, including cardiorespiratory
parameters and temperature, psychomotor development, exploratory behavior, arthro-, nephro- and
hepato-toxic effects. We found no effect of Ciproﬂoxacin at 10 and 30 mg/kg/day. In contrast, adminis-
tration at 100 mg/kg/day delayed weight gain, impaired cardiorespiratory and psychomotor develop-
ment, caused inﬂammatory inﬁltrates in the connective tissues surrounding the knee joint, and
moderately increased extramedullary hematopoiesis. The present study pleads for careful watching of
cardiorespiratory and motor development in neonates treated with Ciproﬂoxacin, in addition to the
standard surveillance of arthrotoxicity.
© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
Ciproﬂoxacin is a synthetic broad-spectrum antimicrobial agent,
belonging to the ﬂuoroquinolone family, and considered as effec-
tive against a wide range of Gram-positive and Gram-negativeRobert Debre, 48 Bd Serurier,
).
r Inc. This is an open access articleorganisms. Ciproﬂoxacin interferes with DNA function by inhibiting
bacterial DNA gyrate and topoisomerase IV, which are required for
bacterial DNA replication, transcription, repair and recombination.
Ciproﬂoxacin is the only ﬂuoroquinolone to be included on the list
of “Essential Medicines for Children” by WHO.1 Ciproﬂoxacin was
approved for use in children 1 through 17 years of age in 2004, but1 http://www.who.int/medicines/publications/TRS958June2010.pdf. Accessed
July 28 2014.
under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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Fig. 1. Overview of our safety study of Ciproﬂoxacin in newborn mice. Arrows: All
animals received a daily SC administration of Ciproﬂoxacin (0, 10, 30 or 100 mg/kg)
from PND2 to PND12 (11 injections). Triangles: Animals (N ¼ 230) were sacriﬁced to
collect blood samples. Squares: Physiological and behavioral testing (N ¼ 120), and
psychomotor testing (N ¼ 120) were carried out at PND4, PND9 and PND14. Circles:
joints, kidneys and liver were collected at PND14 (N ¼ 60) and PND60 (N ¼ 56) to
assess arthro-, nephro- and hepato-toxic effects of Ciproﬂoxacin.
T. Bourgeois et al. / Regulatory Toxicology and Pharmacology 74 (2016) 161e169162not in neonates (Bradley et al., 2011). However, Ciproﬂoxacin may
be prescribed “off-label” for the treatment of suspected or proven
gram negative infections in neonates, especially if premature. In
such context, data evaluating potential neurodevelopmental
toxicity as well as joint and hepatic toxicity are missing (Bradley
et al., 2011; Forsythe and Ernst, 2007; Kaguelidou et al., 2011;
Sendzik et al., 2009).
In order to gather information on the possible short- and long-
term adverse effects of Ciproﬂoxacin, the European Medicines
Agency (EMA) has included Ciproﬂoxacin in its priority list of off-
patent medicinal products for evaluation in the pediatric popula-
tion.2 The evaluation of Ciproﬂoxacin is currently ongoing by the
TINN EU project (Treat Infections in Neonates3), in view of the
submission of a Pediatric Use Marketing Authorization (PUMA) for
Ciproﬂoxacin in neonates (Jacqz-Aigrain, 2011). The present pre-
clinical study was conducted as part of the TINN project to assess
the potential adverse effects of Ciproﬂoxacin on development in
juvenile mice.
In order to assess the developmental effects of Ciproﬂoxacin, we
exposed pre-weanling mice to Ciproﬂoxacin from 2 to 12 days of
postnatal age (PND2 to PND12). Firstly, we examined the possible
neurotoxic effects of Ciproﬂoxacin chronic administration on neu-
rodevelopment with a special focus on breathing and psychomotor
developments, which are both particularly critical in preterm in-
fants. Then, we looked for effects of Ciproﬂoxacin on kidneys and
liver development, considering previous reports that Ciproﬂoxacin
caused a higher overall risk of hepatotoxicity (Alshammari et al.,
2014). Finally, we examined whether Ciproﬂoxacin produced
anarthrotoxic effect, as previously observed in weight bearing
joints of juvenile animals and also in pediatric populations
(Adefurin et al., 2011).
2. Material and methods
2.1. Test substance
Solutions (40 mL) of 1 mg/mL, 3 mg/mL and 10 mg/mL Cipro-
ﬂoxacin and a control solution without Ciproﬂoxacin were pre-
pared in sterile water for injection (5% glucose, Freeﬂex®, Fresenius
Kabi, France) with Ciproﬂoxacin powder (SigmaeAldrich, Ger-
many), lactic acid (8, 24, 80 and 20 mg, respectively) and chloride
acid (40 mL). The pHwas adjusted to pH 5with sodium hydroxide in
all solutions, except the 10mg/mL solution inwhich it was adjusted
to pH 4. Afterwards, solutions were transferred into sterile vials
through 0.2 mm syringe ﬁlters (Pall PharmAssure, Pall Medical,
France). These solutions were prepared under a laminar airﬂow
cabinet and controlled by the Pharmacy Department of Robert
Debre Hospital in Paris.
2.2. Animals
Mouse pups (N ¼ 230 for blood sampling, N ¼ 150 for physio-
logical and locomotion tests, andN¼ 150 for psychomotor tests and
organs collection) were obtained from outbred Swiss female mice
(Charles River Lab, France) housed at 20 C ± 1 C with a 12 h light/
dark cycle and fed ad libitum (SAFE, France). All litters were born
between 8 pm and 8 am. The ﬁrst day following birth was denoted
Postnatal Day 0 (PND0). Unless mentioned otherwise, litters were
culled the day of birth to obtain 10 pups per litter, and housed
individually in standard Plexiglas cages (Tecniplast, France). The2 EMEA/197972/2007; http://www.phytonetzwerk.de/Veranstaltungen/Kind_in_
der_Apotheke/PNM_Sickmueller-EMEA_Stoffe_Off%20patent_May_2007en.pdf.
3 http://www.tinn-project.org/.animals were weighted daily from PND2 to PND14, and at PND16,
PND21, PND30, PND41 and PND60. Animals were killed by decap-
itation at PND14 or by cervical dislocation at PND60. The overview
of Ciproﬂoxacin safety testing in newbornmice is indicated in Fig. 1.
The present study complies with the EMA guidelines on the
need for non-clinical testing in juvenile animals of pharmaceuticals
for pediatric indications.4 All the protocols were performed in
accordance with the European Communities Council Directive
(2010/63/UE) regarding the care and use of animals for experi-
mental procedures, in compliance with the French regulations of
the Ministere de l’Agriculture et de la Fore^t, Service Veterinaire de la
Sante et de la Protection Animale (permission # A 94-028-21) and
were approved by the Institutional Ethics Committee (Bichat-
Robert-Debre) and national committees (Ministere de l’Enseigne-
ment Superieur et de la Recherche e Direction Generale pour la
Recherche et l’Innovation). All efforts were made to minimize an-
imal suffering, especially by using non-invasive functional tests
specially designed for newborn rodents.
2.3. Administration-route and doses
Ciproﬂoxacin was administered subcutaneously (SC). In
newborn mice, intraperitoneal (IP) administration is poorly suited
to chronic administration due to the risk of infection; oral admin-
istration is potentially harmful before PND12; intramuscular
administration is difﬁcult because of the paucity of muscle bulk;
and intravenous (IV) administration is technically problematic
because of the small size of blood vessels. We used a maximum
dose of 100 mg/kg/day and intermediate doses of 10 and 30 mg/kg/
day.
Ciproﬂoxacin solutions were administered once daily from
PND2 to PND12 (11 injections per animal) at doses of 10 or 100 mg/
kg/day in the blood sampling study, or at doses of 0, 10, 30 or
100 mg/kg/day in the physiological, psychomotor and behavioral
studies. SC injections were alternatively performed at three
different sites in the back of the mice, in order to minimize skin
lesions.
2.4. Plasma levels
Blood samples were obtained from decapitation of three to ﬁve
mice, pooled in an EDTA tube and centrifuged (4200 rpm at 4 C) to
obtain one plasma sample of 150 mL approximately and refrigerated4 http://www.ema.europa.eu/docs/en_GB/document_library/Scientiﬁc_
guideline/2009/09/WC500003306.pdf.
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PND2 to PND12 at doses of 10 and 100 mg/kg SC. Blood was
collected 30min and 23 h after the ﬁrst injection at PND2, 23 h after
injection at PND6 and PND11, and 30min and 23 h after injection at
PND12. Five samples were collected at each time point and for both
doses. The analytical method of Ciproﬂoxacin has been reported
previously (Grondin et al., 2011). Brieﬂy, Ciproﬂoxacin concentra-
tions were determined using high-performance liquid chroma-
tography with mass spectrometry with Ciproﬂoxacin-d8 as internal
standard. The calibration curve ranged from 25 to 3000 ng/mL. The
inter- and intra-day coefﬁcients of variation (CVs) of controls were
4.1% and 2.4%, respectively. The lower limit of quantiﬁcation was
25 ng/mL.
2.5. Physiological testing
Physiological testing was carried out at PND4, PND9 and PND14
in the four dose groups (30 animals per dose group). We measured
vital functions (breathing and activity, heart rate and body tem-
perature) simultaneously in a plethysmographic chamber, in
baseline conditions (10 min) and in response to chemical stimuli
(hypoxic and hypercapnic challenges). The total duration of phys-
iological testing for each mouse was 30 min.
Breathing variables were measured non-invasively using a bat-
tery of four whole-body ﬂow barometric plethysmographs, as
previously described (Miot et al., 2012). Plethysmograph chambers
were immersed in a thermoregulated water-bath that maintained
their temperature at 33 C, which is close to thermoneutrality in
newborn rodents (Blumberg and Sokoloff, 1998). Because of the
limitations of ﬂow barometric plethysmography (Enhorning et al.,
1998; Mortola and Frappell, 1998), the absolute values of tidal
volume (VT) and ventilation (VE) are indicative only, whereas
breathing frequency absolute values (f) and apnea durations are
reliable. Breathing frequency (f, breaths/min), tidal volume (VT, ml/
g), and minute ventilation (VE, calculated as (VT x f/60) and
expressed in ml/s/g) were calculated on apnea-free periods (see
apnea determination below). Each mouse was exposed to an hyp-
oxic and an hypercapnic challenge to test for respiratory reﬂexes.
After 10-min normoxia, hypoxia was achieved by switching the
airﬂow through the plethysmograph to 10% O2 þ 90% N2 at the
same ﬂow rate (200ml/min per chamber) for 3min, after which the
ﬂow was switched back to normoxia for 7 min. Similarly, hyper-
capnia was achieved by switching the airﬂow to 8% CO2 þ 21% O2 þ
71% N2.
The baseline (i.e. normoxic/normocapnic) levels for breathing
variables were calculated as the mean value over the 3-min of air
breathing preceding the hypoxia or hypercapnia challenge. Breath-
by-breath values for VE, VT, and f were averaged over consecutive
30-sec periods for the peak determination. Each individual peak VE
value was calculated as the maximum mean value over a 3-min
period starting 30 s after the gas switch, to take into account
possible interindividual differences in time to reach the peak VE
response to hypoxia or hypercapnia and washout of the chamber.
VE response to hypercapnia was expressed as the percentage VE
change relative to baseline average VE, using the formula 100 x
(peak VE - baseline VE)/baseline VE. We determined VT and f re-
sponses to hypoxia and hypercapnia using the same formula,
knowing that peak values were calculated as the mean of VT and f
over the 30 s period during which VE was found to be maximum.
Apneas were deﬁned as ventilatory pauses longer than 0.7 s,
which is approximately twice the duration of a normal breath in
PND4, PND9 and PND14 Swiss mice pups. Apneas were determined
using an automatic classiﬁcation method (Matrot et al., 2005). Ac-
tivity was detected based on large disturbances in the respiratory
signal caused by the combined effects of positional changes insidethe chamber and changes in breathing pattern. These disturbances
in the respiratory signal were detected using the following crite-
rion: {(Vi-Ve)/(Viþ Ve)}, where Vi and Ve are themagnitudes of the
inspiratory and expiratory limbs of the volume signal, respectively.
This automatic detection method was previously validated against
visual scoring of movements (Matrot et al., 2005). Apnea duration
and activity were expressed as a percentage of recording time
during the 10-min period preceding the hypoxic challenge.
Each chamber was equipped with an electrocardiographic (ECG)
recording platform composed of four rectangular gold electrodes
insulated from one another and embedded in the ﬂoor of the
chamber, as previously described (Ramanantsoa et al., 2007). An
ECG signal was obtained when at least three paws contacted three
electrodes and, occasionally, when the pup laid on the ﬂoor over
three electrodes. Heart rate (HR in beats/min, BPM) was deter-
mined from the R-Rwave peaks detected automatically by a custom
program (Christov, 2004). The baseline HR was calculated for each
individual during the 10-min normoxia period at the beginning of
the procedure.
Wemeasured body temperature non-invasively in PND4 pups in
the plethysmograph chamber. This was done by measuring the
emission of infrared (IR) radiations from surface of the inter-
scapular region using an infrared camera (FLIR Systems Thermo-
vision A20, MA) as described (Ramanantsoa et al., 2011). The
interscapular region contains the heat-generating brown adipose
cells and is the area of highest skin temperature (Blumberg and
Sokoloff, 1998). The camera was moved over each of the four ani-
mal chambers every 1 min 15 s. IR measurement was done through
a special window of the plethysmograph chamber made of Zinc
Selenide, to ensure permeability to IR emission. We previously
showed that the non-invasive measurements of IR interscapular
temperature and oesophageal temperatures were highly correlated
(Bollen et al., 2009). IR temperature was not collected at PND9 and
PND14 because fur precluded this technique. We measured tem-
perature of all pups in room environment at PND4, PND9 and
PND14, before and after physiological testing by placing a ther-
mocouple probe at the level of the interscapular region.
2.6. Psychomotor development
We used three tests from Fox battery (Fox,1965): righting reﬂex,
cliff-drop aversion, and negative geotaxis. The tests were per-
formed this order, at 26 C. Righting reﬂex: each pup was placed on
its back on a non-slippery surface. We recorded the time needed by
the pup to regain its feet. A maximum time of 30 s was given to
complete the task. Pups not able to complete the task were given
the maximum time of 30 s. Cliff-drop aversion reﬂex: each pup was
placed on the edge of an elevated platform, with both front paws
over the edge. We recorded the time needed for the pup to crawl
away from the edge. Negative geotaxis: each pup was placed with
the head facing downward with an angle of 30 at PND4 and PND9,
and of 45 at PND14. We recorded the time needed for the pup to
turn until it faced up the slope. The failure to complete any test was
scored 0 (1 otherwise; mean score per group x100 indicated the
proportion of mice that completed the test in this group).
2.7. Exploratory behavior
Weperformed open-ﬁeld tests at PND4, PND9 and PND14with a
custom, thermoregulated open-ﬁeld system at 26 C, as previously
described (Dehorter et al., 2011). Each mouse was placed on a
transparent acrylic plate (50 cm  60 cm) covered with a silicone
gel and its activity was tracked for 1 min. A camera recorded the
trajectory of the pup. We determined the explored zones and the
total distance traveled using custom software.
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Elbow and knee joints were collected at PND14. Limbs were
disarticulated from axial skeleton, and soft tissue partially
removed. The joints were radiographed using a Faxitron (Hewlett
Packard, USA). The lengths of intact humeri, tibiae and ﬁbulae were
measured using numerized X-rays. Limbs were ﬁxed in 4% buffered
formalin. Decalciﬁcation was done in 0.1M EDTA. After parafﬁn
embedding, 4 mm thick longitudinal sections of the entire limbs
were cut using a rotary microtome. Routine staining with Haemo-
toxylin Eosin and Saffron and PAS staining were performed. His-
tological analysis of the bone and cartilage was performed in order
to detect degenerative, necrotic or abnormal bone or cartilage
formation.
2.9. Liver and kidney histology
Livers were collected at PND14 (N ¼ 60) and PND60 (N ¼ 56),
were ﬁxed in formalin and embedded in parafﬁn. Sections were
stained with HES (hematoxylin, eosin and saffron) and Masson's
trichrome to assess epithelial cells, vessels and connective tissues.
In addition, we quantiﬁed the number of hematopoiesis foci per
hepatic lobule. A similar analysis was conducted on kidneys.
2.10. Statistical analysis
All study variables were analyzed using repeated measure
analysis of variance (ANOVA) with treatment (0, 10, 30, 100 mg/kg/
day Ciproﬂoxacin), litter and gender as between-subjects factors
and age as a repeated factor. Weights from PND2 to PND14 and
from PND16 to PND60 were analyzed separately. Unless speciﬁed,
litter and gender had no signiﬁcant effects, either as amain effect or
in interaction with treatment. When appropriate, pairwise com-
parisons were done using the Fischer's PLSD with Bonferroni
correction. Statistical analyses were conducted using R software
(www.r-project.org).
3. Results
3.1. Local tolerance to injections
The mice receiving 0, 10, and 30 mg/kg/day did not show any
sign of pain or local irritation at the sites of injection. In contrast,
the mice receiving 100 mg/kg/day showed signs of cutaneous
inﬂammation in the region of SC injections (skin rash, hair loss, and
skin necrosis) as early as PND5 (i.e. after three injections) and until
PND60. These mice also showed defensive responses indicative of
irritation after SC injection until PND7 and scratching for about
1 min beyond this age. These responses vanished completely
beyond this delay.
3.2. Ciproﬂoxacin plasma concentration
Peak plasma Ciproﬂoxacin concentrations (30 min after injec-
tion) were similar at PND2 and PND12 for both 10 mg/kg and
100 mg/kg daily injections (Table 1). Trough plasma concentrations
at PND3, PND7 and PND13 were below 0.5 mg/L for both doses
(Table 1).
3.3. Clinical observation and weight gain
Ciproﬂoxacin treatment did not inﬂuence general appearance,
behavior and mortality throughout the study period. However,
100 mg/kg/day Ciproﬂoxacin signiﬁcantly reduced weight gain
from PND2 to PND14 (weight by age interaction F ¼ 10.82,p < 0.001, and partial comparisons shown in Fig. 2A). There was no
effect of sex over the PND2-PND14 period. From PND16 to PND60,
weights were not found signiﬁcantly different between dose
groups, neither in females (N ¼ 60) nor in males (N ¼ 58, Fig. 2B).3.4. Physiological testing
As a rule, Ciproﬂoxacin treatment did not signiﬁcantly affected
physiological variables and activity (Table 2 and Supplementary
Fig. 1AeC). However, breathing frequency (f) responses to hypox-
ia at PND4 displayed a marginally signiﬁcant effect of dose
(F ¼ 2.805, p ¼ 0.043, all pairwise comparisons between dose
groups were not signiﬁcant). This difference did not signiﬁcantly
impact VE and was of limited biological signiﬁcance. Also, the VE-
response to hypercapnia displayed a marginally signiﬁcant inter-
action between sex and dose (F ¼ 2.88, p ¼ 0.039). Examination of
individual data revealed that this effect is linked to the high VE-
response to hypercapnia in 3 out of 13 female pups in the 100 mg/
kg/day group. Ciproﬂoxacin treatment had no signiﬁcant effect on
heart rate (Table 2) and body temperature (Supplementary Fig. 2).
In summary, the effect of Ciproﬂoxacin on physiological variables
was limited to modest ventilatory changes in the 100 mg/kg/day
group.3.5. Psychomotor development
On PND4, the righting reﬂex was signiﬁcantly impaired in mice
receiving 100 mg/kg/day compared to controls (F ¼ 2.83, p ¼ 0.038
and pairwise comparisons shown in Table 3). This effect born upon
the impairments of males, who showed lower scores compared to
control (p ¼ 0.020) and 10 mg/kg/day groups (p ¼ 0.044), whereas
females showed similar scores (group by gender interaction:
F ¼ 3.21, p ¼ 0.023). The defect observed in male pups receiving
100 mg/kg/day vanished on PND9, when all the pups performed
the test very quickly. This test was not performed on PND14, due to
the impossibility to measure the short time needed by all the pups
to regain their feet. Cliff-drop aversion scores improved from PND4
to PND9 in all groups but did not reveal signiﬁcant effects of
treatment (Table 3). Finally, negative geotaxis scores did not indi-
cate signiﬁcant effects of Ciproﬂoxacin treatment at any dose. In the
100 mg/kg/day group, fewer pups completed the test compared to
other groups, although not signiﬁcantly (Table 3). However, the
pups that did complete the test needed signiﬁcantly shorter times
to do so, likely thanks to their smaller weight (Table 3). Thus, the
psychomotor testing indicated a transient delay in righting test
acquisition in the high dose group.3.6. Exploratory behavior
The distance traveled increased with age (as a normal effect of
development) with no signiﬁcant effect of Ciproﬂoxacin treatment
(Table 4). The explored zones did not show any signiﬁcant effect of
treatment.3.7. Joints histology and bone length
Histology of humero-ulnar joints with HES staining did not
indicate cartilage alteration at any age, and for any dose
(Fig. 3AeD). However, the connective tissues surrounding the knee
joint displayed moderate inﬂammatory inﬁltrates in the 100 mg/
kg/day group at PND14 (Fig. 3C and D). Bone lengths were not
signiﬁcantly inﬂuenced by Ciproﬂoxacin treatment (Table 5 and
Fig. 3E).
Table 1
Plasma concentration of Ciproﬂoxacin in mice treated with daily doses of Ciproﬂoxacin 10 or 100 mg/kg SC from PND2 to PND12 (Adm1 to Adm11).
Adm. 1 þ 300 Adm. 1 þ 23 h Adm. 5 þ 23 h Adm. 10 þ 23 h Adm. 11 þ 300 Adm. 11 þ 23 h
Age PND2 PND3 PND7 PND12 PND12 PND13
Pooling 5 5 4 3 3 3
Pups remaining per litter 7 to 8 5 to 6 3 to 4 2 to 3 1 to 2
10 mg/kg/day
Weight (g) 2.21
(0.17)
2.89
(0.26)
4.05
(0.55)
8.01
(0.69)
7.29
(0.41)
9.25
(0.66)
Plasma concentration (mg/l) 1.86
(0.32)
0.02
(0.02)
0.02
(0.01)
0.00
(0.00)
2.28
(0.25)
0.00
(0.00)
100 mg/kg/day
Weight (g) 2.07
(0.23)
2.48
(0.49)
4.65
(0.29)
8.33
(0.94)
6.74
(0.52)
9.25
(1.04)
Plasma concentration (mg/l) 10.35
(2.00)
0.47
(0.18)
0.15
(0.03)
0.09
(0.03)
10.57
(1.03)
0.08
(0.03)
Values are groupmeans (Standard Deviation, SD). Blood samples were collected and pooled 30min after the ﬁrst and 11th administration and 23 h after the ﬁrst, 5th, 10th and
11th administration. Pooling indicates the number of individual samples pooled together. Animals used for sampling were randomly chosen among litters.
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Fig. 2. Weight gain from PND2 to PND14 (A) and from PND16 to PND60 (B). A: weight gain was inﬂuenced by treatment (N ¼ 59, N ¼ 58, N ¼ 60, N ¼ 60 for 0, 10, 30 and 100 mg/kg/
day, respectively), and from PND8 to PND14, animals of the 100 mg/kg/day group were signiﬁcantly lighter than controls. There were no signiﬁcant differences between 0, 10 and
30 mg/kg/day dose groups at any age. Weights are notably smaller than those indicated in Table 1, due to larger litter sizes. B: Weight gain from PND16 to PND60 (N ¼ 18, N ¼ 17,
N ¼ 12, N ¼ 13 females, and N ¼ 11, N ¼ 12, N ¼ 18, N ¼ 17 males for control, low, mid and high dose, respectively) was not inﬂuenced by treatment in females and males. Note the
different scales. Pairwise comparisons differences between 0 and 100 mg/kg/day dose groups; *: p < 0.05, **: p < 0.005, ***: p < 0.0005 for partial comparison between 0 and
100 mg/kg/day dose groups. Values are group means. Error bars are SD.
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The kidneys were histologically normal. In the liver, no archi-
tectural modiﬁcation, ﬁbrosis, necrosis, steatosis, vascular lesion,
bile duct proliferation or granuloma were observed. Two days after
the last injection (i.e. at PND14), the number of hematopoiesis foci
in the 10 mg/kg/day (4.7 ± 1.9) and in the 30 mg/kg/day (5.1 ± 1.9)
groups were not different compared to controls (4.5 ± 1.6). In
contrast, mice receiving 100 mg/kg/day Ciproﬂoxacin had signiﬁ-
cantly more numerous hematopoiesis foci per hepatic lobule
(7 ± 2.2) compared to controls (p ¼ 0.0041), to the 10 mg/kg/day
group (p ¼ 0.010) and to the 30 mg/kg/day group (p ¼ 0.048). We
observed no architectural modiﬁcation, ﬁbrosis, necrosis or vacu-
olation of liver cells, steatosis or vascular lesion, bile duct prolifer-
ation, nor granuloma.4. Discussion
The present study assessed potential toxic effects of Ciproﬂox-
acin administered SC once daily at 10, 30 and 100 mg/kg dose from
PND2 to PND12 in newborn mice. In addition to weight gain and
arthro-, nephro-, and hepato-toxicity, we examined, for the ﬁrst
time, potential neurodevelopmental toxicity affecting cardiorespi-
ratory function, psychomotor development and exploratorybehavior. The main results were that, at 10 and 30 mg/kg/day, there
were no Ciproﬂoxacin related effects on any study parameter, while
administration of 100 mg/kg/day transiently delayed weight gain,
had small effects on physiological variables, and affected joints and
liver development. In contrast, psychomotor development and
exploratory behavior were spared in this dose group, showing the
limits of toxicity of Ciproﬂoxacin in newborn mice.
4.1. Period of treatment
The study period is a critical aspect of safety studies in juvenile
animals, because the animals must be tested at developmental
stages corresponding to those of the target pediatric population. To
fulﬁll this requirement, we administered Ciproﬂoxacin from PND2
to PND12. This period covers the period during which Ciproﬂoxacin
may be administered in preterm infants, considering that, from a
neurodevelopmental perspective, P2 in rodents corresponds to
about 25e28 weeks of gestation in humans and P12 slightly ex-
ceeds full term (Craig et al., 2003; Semple et al., 2013).
4.2. Clinical relevance of the doses
The doses used in the present study (10, 30, 100 mg/kg/day, SC)
were akin to those used in neonates, which range from 3 to 94 mg/
Table 2
Cardiorespiratory variables, activity, heart rate and body temperature measured in a thermoregulated plethysmographic chamber.
Dose (mg/kg/day) PND4 PND9 PND14
0 10 30 100 0 10 30 100 0 10 30 100
N 29 28 30 30 29 28 30 30 29 28 30 30
females/males 13/16 11/17 11/19 13/17 13/16 11/17 11/19 13/17 13/16 11/17 11/19 13/17
Weight (g) 2.98
(0.26)
2.95
(0.23)
2.95
(0.30)
2.85
(0.25)
5.56
(0.49)
5.44
(0.40)
5.38
(0.41)
5.15
(0.36)
7.33
(0.65)
7.09
(0.64)
6.94
(0.77)
6.59
(0.48)
Baseline values
VE (ml/s/g) 31.2
(6.4)
31.0
(6.9)
31.2
(7.6)
33.1
(5.9)
22.9
(4.5)
21.6
(3.9)
21.4
(3.8)
20.8
(4.1)
30.9
(9.9)
29.4
(8.2)
32.8
(8.6)
31.6
(13.3)
VT (ml/g) 9.7
(1.1)
9.7
(1.5)
9.6
(1.5)
9.5
(1.4)
7.7
(1.1)
7.6
(1.0)
7.6
(1.0)
7.7
(1.0)
10.4
(1.6)
10.1
(1.7)
10.4
(2.3)
10.3
(1.9)
f (breaths/min) 191.6
(28.3)
193.0
(32.4)
193.5
(28.3)
208.4
(23.6)
179.5
(27.5)
170.9
(28.3)
169.6
(30.8)
163.8
(29.9)
177.5
(37.9)
175.0
(41.2)
197.3
(58.3)
186.3
(64.7)
Apneas (%) 0.6
(1.0)
0.9
(2.6)
0.6
(1.3)
0.2
(0.4)
0.9
(0.9)
1.1
(1.4)
1.4
(1.9)
1.5
(1.7)
1.0
(1.6)
0.9
(1.6)
0.9
(1.9)
1.2
(1.5)
Activity (%) 17.9
(15.1)
19.6
(15.6)
17.5
(9.7)
15.8
(10.2)
18.4
(16.9)
14.3
(11.9)
11.6
(12.7)
10.7
(9.7)
65.3
(28.3)
67.8
(25.6)
67.0
(23.5)
64.1
(26.2)
HR (bpm) 517.3
(41.7)
506.0
(33.9)
518.9
(36.6)
533.6
(26.0)
536.5
(46.6)
520.8
(44.9)
522.5
(38.3)
501.3
(51.3)
583.1
(35.2)
603.9
(37.2)
598.7
(61.9)
588.3
(48.1)
Temp before (C) 34.8
(0.8)
34.9
(0.7)
35.0
(0.7)
34.9
(0.6)
35.0
(0.7)
35.0
(0.9)
35.2
(0.6)
35.2
(0.7)
35.9
(0.6)
35.6
(0.9)
36.1
(0.4)
35.8
(0.7)
Temp after (C) 34.8
(0.8)
34.9
(0.8)
35.0
(0.8)
35.0
(1.0)
35.6
(0.4)
35.6
(0.3)
35.6
(0.4)
35.6
(0.4)
36.9
(0.5)
36.7
(0.5)
36.7
(0.5)
36.6
(0.4)
Response to hypoxia
VE (%) 78.6
(34.9)
67.8
(28.1)
70.9
(18.1)
60.4
(18.9)
92.6
(31.6)
97.2
(22.4)
102.2
(26.7)
94.8
(27.3)
90.9
(39.7)
89.0
(42.0)
76.9
(38.8)
83.6
(58.6)
VT (%) 16.2
(17.5)
12.1
(12.3)
13.4
(9.4)
13.0
(9.5)
11.8
(12.7)
12.8
(10.5)
12.9
(11.3)
10.3
(14.1)
12.7
(18.6)
9.9
(22.1)
12.7
(17.0)
9.8
(23.6)
f (%) 53.3
(14.7)
49.6
(17.0)
51.8
(20.6)
42.0
(11.7)
72.4
(23.0)
75.8
(20.6)
80.3
(25.2)
78.6
(30.0)
70.8
(33.8)
76.3
(39.3)
57.4
(35.8)
66.5
(44.9)
Response to hypercapnia
VE (%) 138.6
(69.3)
125.2
(41.6)
120.0
(56.8)
111.2
(44.0)
100.7
(40.8)
117.1
(64.9)
123.0
(67.9)
139.3
(83.2)
398.1
(200.7)
331.4
(188.0)
365.1
(161.7)
297.5
(202.9)
VT (%) 63.6
(31.4)
53.1
(19.1)
52.7
(20.7)
52.1
(24.5)
50.0
(16.8)
54.9
(17.8)
58.9
(23.2)
58.3
(24.2)
116.2
(35.9)
103.6
(42.4)
108.3
(32.9)
95.5
(39.3)
f (%) 45.7
(30.3)
47.2
(19.5)
45.4
(37.6)
39.8
(26.8)
34.0
(24.1)
39.5
(32.7)
38.8
(29.2)
49.0
(34.1)
126.0
(73.5)
109.5
(73.2)
120.3
(59.2)
95.5
(68.1)
Values are group means (SD). Baseline values and ventilatory responses to hypoxic and hypercapnic challenges expressed as percent increases from baseline levels. Abbre-
viations: VE: ventilation; VT: tidal volume; f: breathing frequency; Apneas and Activity are expressed as percentage of recording time. HR: heart rate; Temp. before and Temp.
after: interscapular temperature before and after plethysmography in room environment, respectively.
Table 3
Psychomotor development assessed with Fox battery tests.
Dose (mg/kg/day) PND4 PND9 PND14
0 10 30 100 0 10 30 100 0 10 30 100
N 30 30 30 30 30 30 30 30 30 30 30 30
females/males 18/12 18/12 12/18 13/17 18/12 18/12 12/18 13/17 18/12 18/12 12/18 13/17
Weight (g) 3.35
(0.42)
3.47
(0.33)
3.42
(0.34)
3.34
(0.29)
5.99
(0.55)
6.20
(0.37)
6.06
(0.51)
5.79
(0.38)
7.80
(0.59)
8.02
(0.47)
7.78
(0.70)
7.21
(0.52)
Righting reﬂex
Score  100 68
(47)
56
(50)
59
(49)
47*
(50)
100
(0)
100
(0)
100
(0)
100
(0)
NA NA NA NA
Time (s) 7.2
(8.5)
5.3
(7.8)
6.6
(8.4)
4.7
(6.8)
<1 <1 <1 <1 NA NA NA NA
Cliff-drop aversion
Score x 100 78
(42)
74
(44)
68
(47)
71
(46)
98
(15)
96
(21)
96
(21)
98
(15)
NA NA NA NA
Time (s) 7.1
(8.0)
6.0
(7.8)
5.1
(6.6)
6.3
(7.9)
1.9
(1.5)
1.6
(0.9)
1.6
(1.6)
1.8
(0.9)
NA NA NA NA
Negative geotaxis
Score x 100 70
(46)
64
(48)
69
(47)
64
(48)
88
(33)
91
(29)
84
(36)
82
(38)
73
(44)
64
(48)
67
(47)
54
(50)
Time (s) 8.2
(8.0)
7.2
(8.0)
7.2
(7.2)
6.3
(6.7)
8.5
(7.1)
8.2
(6.9)
7.3
(6.2)
6.4
(7.1)
4.0
(4.9)
2.9
(3.6)
2.8
(3.1)
1.5*
(1.8)
Values are groupmeans (SD). Righting reﬂex, Cliff-drop aversion, Negative geotaxis: success rate and time before success as described in Section 2.6. Pairwise comparison with
controls: *: p < 0.05.
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is 10e30 mg/kg/day in at least 60% of studies, generally adminis-
tered in two divided doses for both oral and IV routes (Adefurin
et al., 2011).Plasma levels, which are moremeaningful than doses for correct
comparisons between animal and human studies, conﬁrmed the
clinical relevance of the present preclinical protocol. For example,
IV Ciproﬂoxacin at the dose of 10 mg/kg, 12 hourly in preterm
Table 4
Exploratory behavior.
Dose (mg/kg/day) PND4 PND9 PND14
0 10 30 100 0 10 30 100 0 10 30 100
N 29 28 30 30 29 28 30 30 29 28 30 30
females/males 13/16 11/17 11/19 13/17 13/16 11/17 11/19 13/17 13/16 11/17 11/19 13/17
Weight (g) 3.00
(0.26)
2.92
(0.22)
2.93
(0.26)
2.87
(0.25)
5.58
(0.50)
5.46
(0.42)
5.41
(0.43)
5.17
(0.38)
7.31
(0.67)
7.13
(0.67)
6.97
(0.80)
6.62
(0.52)
Open-ﬁeld test
Distance traveled (AU) 40.4
(28.3)
45.3
(26.8)
38.7
(37.6)
45.3
(31.3)
46.9
(28.2)
59.0
(33.2)
43.5
(23.7)
67.9
(32.3)
76.0
(54.0)
73.8
(49.4)
74.5
(46.3)
85.3
(59.2)
Values are group means (SD). Distance traveled (in arbitrary units, AU) during an open ﬁeld test for 1-min.
Fig. 3. Cartilage joints of juvenile (PND14) and adult (PND60) mice treated with daily doses of Ciproﬂoxacin 0, 10, 30 or 100 mg/kg/day SC from PND2 to PND12. A: histological
section of humero-ulnar joint, stained with HES at PND14 in one mouse of the 100 mg/kg/day group. Scale bar: 1 mm. B: magniﬁcation (x20) of the region delineated in A. No
cartilage alteration was observed in any dose group at PND14 and PND60. Scale bar: 150 mm. C: Histological section of muscular and connective tissues surrounded the knee joint,
stained with HES at PND14 in one animal of the 100 mg/kg/day group. Scale bar: 1 mm. D: magniﬁcation (x20) of the region delineated in C. Note the presence of moderate
inﬂammatory inﬁltrates (arrows) in these tissues, found only in the 100 mg/kg/day dose group at PND14. Scale bar: 150 mm. E: X-ray image of the skeleton of an animal of the
100 mg/kg/day group at PND14. No anomalies of bone length and maturation were detected in any dose group at PND14 and PND60. b: bone; c: cartilage. Scale bar: 10 mm.
Table 5
Skeletal imaging in juvenile (PND14) and adult (PND60) mice.
Dose (mg/kg/day) PND14 PND60
0 10 30 100 0 10 30 100
N 15 15 15 15 14 13 14 15
females/males 7/8 6/9 3/12 4/11 6/8 5/8 7/7 9/6
Weight (g) 7.25
(0.73)
6.90
(0.63)
6.91
(0.56)
6.50
(0.55)
36.67
(4.71)
36.92
(4.92)
36.00
(6.24)
33.34
(4.06)
Bone Length
Humerus 53.7
(10.5)
54.2
(11.5)
54.9
(12.4)
53.1
(11.2)
115.3
(17.6)
113.4
(18.8)
114.9
(17.9)
115.0
(20.8)
Radius-cubitus 71.2
(11.9)
72.1
(12.7)
73.8
(14.6)
70.9
(13.2)
126.5
(18.7)
123.3
(21.2)
125.9
(19.3)
126.5
(22.1)
Femur 52.5
(8.7)
53.0
(8.2)
52.9
(10.6)
51.4
(10.0)
146.6
(22.1)
142.1
(23.7)
145.7
(22.1)
144.2
(24.0)
Tibia-ﬁbula 83.8
(16.2)
83.3
(16.5)
84.3
(17.4)
81.9
(17.4)
165.1
(25.5)
158.9
(26.1)
163.4
(25.8)
162.5
(26.7)
Values are group means (SD).
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ranged from 2.3 to 3.0 mg/mL (Aggarwal et al., 2004; Kaguelidou
et al., 2011) and trough concentrations ranged from 0.7 to 1.0 mg/
mL. These values are of the same order of magnitude as levels
measured in newborn mice in the present study (1.86 and 2.28 mg/
mL), 30 min after administration in the 10 mg/kg/day group.
Recently, a population pharmacokinetics study conducted at doses
of 20e30 mg/kg/day in neonates and young infants of less than
three months found ciproﬂoxacin levels ranging from 0.5 to
16.0 mg/mL (Zhao et al., 2014). This study showed that babiestreated with ciproﬂoxacin can be exposed to high plasma levels,
which can be compared with those measured in newborn mice in
the present study, 30 min after administration in the high dose
group (100 mg/kg/day, 10.35 and 10.57 mg/mL). Taken together, the
doses and resulting plasma levels support the design of the present
neurodevelopmental toxicity study.4.3. Delayed weight gain at 100 mg/kg/day
Weight gain delay is a common expression of developmental
T. Bourgeois et al. / Regulatory Toxicology and Pharmacology 74 (2016) 161e169168toxicity. No signiﬁcant adverse effects on weight gain were
observed at 10 and 30 mg/kg/day, in keeping with previous reports
that weight gain was not affected in juvenile mice treated with
50 mg/kg/day from PND7 for 7 or 14 days (Linseman et al., 1995).
The present results extend these previous observations by indi-
cating that Ciproﬂoxacin at usual doses does not affect weight gain
even when administered at an earlier stage of development (i.e.
from PND2), period which roughly corresponds to prematurity in
human infants. In contrast, adverse effects on weight gain were
observed here at the high dose of 100 mg/kg/day, suggesting that
the limit of safety lies between 50 and 100 mg/kg/day. Because
plasma levels measured in the 100 mg/kg/day group correspond to
those measured in neonates treated with ciproﬂoxacin at doses of
20e30 mg/kg/day (as noted above), our data suggest that Cipro-
ﬂoxacin might affect weight gain in humans. However, Ciproﬂox-
acin administered at a lower dose of 10 mg/kg/dose 12-hourly
during the treatment period to very low weight babies did not
affect linear growth until 12 months corrected age (Dutta et al.,
2006).
4.4. No adverse effects on cardiorespiratory variables
The possible adverse effects of Ciproﬂoxacin on breathing are a
particularly critical issue in preterm infants, due to their speciﬁc
risk of respiratory failure. Furthermore, breathing pattern is also
relevant because it is a highly sensitive marker of arousal level and
emotions, all reﬂecting the inﬂuence of higher processes, including
in newborn mice (Durand et al., 2003). As a rule, the cardiorespi-
ratory component of safety assessment has largely not been studied
in neurodevelopmental toxicity studies. As a matter of fact, the
possible adverse effects of Ciproﬂoxacin on these vital functions
were not addressed in neither preclinical or clinical studies
(Kaguelidou et al., 2011). In the present study, we assessed the
cardiorespiratory effects of Ciproﬂoxacin using an innovative plat-
form allowing simultaneous non-invasive measurements in
controlled environmental conditions (Ramanantsoa et al., 2013).
This methodology avoided disturbances of breathing pattern by
experimental conditions and measurement devices. We found that
cardiorespiratory variables were not inﬂuenced by Ciproﬂoxacin
treatment at any dose nor age, although marginal effects, of un-
certain biological signiﬁcance, were observed at 100 mg/kg/day. In
line with previous preclinical studies, this latter observation
conﬁrmed that the dose of 100 mg/kg/day may present a risk for
development.
4.5. Psychomotor development
Neurobehavioral assessment is the gold standard of drug safety
analysis in animal studies. In the present study, this assessment was
based on three tests from the Fox battery (Fox, 1965), which is a
robust method to evaluate psychomotor development that has
been in use for over 30 years. The Fox battery is currently the only
standardized battery of tests in newborn rodents. The three tests
used in the present study (righting reﬂex, cliff-drop aversion, and
negative geotaxis) were chosen for their reproducibility and their
relevance with respect to the study period (Fox, 1965). The righting
reﬂex revealed a transient development delay in the 100mg/kg/day
Ciproﬂoxacin group at PND4, which extended the effects observed
in breathing pattern to psychomotor development.
4.6. Joints histology and bone growth
Detailed histological analysis of joints conﬁrmed that 10 and
30 mg/kg/day did not cause arthrotoxicity. In contrast, we observed
moderate inﬂammatory inﬁltrates in the connective tissuessurrounding knee joint in the 100 mg/kg/day dose group at PND14.
The effect of Ciproﬂoxacin on bone and joints in juvenile mammals
(mice, rats, beagle dogs) has been extensively investigated in
numerous studies (Sendzik et al., 2009), although only few of them
addressed the early postnatal period (Supplementary Table 1).
Taken together, these studies showed the lack of adverse effects of
Ciproﬂoxacin at mild doses, e.g. ~10mg/kg (Bradley et al., 2011) and
showed arthrotoxicity above this dose (Supplementary Table 1). In
mice, arthrotoxicity of Ciproﬂoxacin was reported at 50 mg/kg/day
SC for 7 or 17 days from PND7, and at 200 mg/kg/day SC for 5 days
(Linseman et al., 1995). In young beagle puppies (13e16 week old,
i.e. after weaning), arthrotoxicity was observed during a 14-day
treatment course (oral) at 90 mg/kg/day but not at 30 mg/kg/day
(von Keutz et al., 2004). Of note, in this latter study, arthrotoxic
concentrations of the drugs in plasma corresponded to plasma
levels achieved during therapy in humans (Sendzik et al., 2009). In
lambs, which are felt to approximate human growth rates and ac-
tivity more closely than juvenile beagle dogs or rats (Bradley et al.,
2011), administration of parenteral Ciproﬂoxacin at 15 mg/kg twice
daily for 14 consecutive days in 6e8 week old weanlings did not
impair nor bone growth nor articular development (Sansone et al.,
2009).
Despite species differences in susceptibility to joint lesion and
bone growth impairments caused by Ciproﬂoxacin, the present
results conﬁrm and extend previous results on Ciproﬂoxacin
arthrotoxicity (Bradley et al., 2011; Sendzik et al., 2009). The pre-
sent data are congruent with previous studies in preterm infants
(mean gestational age 33.2 ± 3.83 weeks) showing that Ciproﬂox-
acin at a dose of 20 mg/kg in two divided doses IV for a period of 14
days did not show arthrotoxicity (Chaudhari et al., 2004). However,
a limitation of the present study is that ultrastructural effects of
Ciproﬂoxacin on joints were not analyzed. Such toxic effects have
been detected in Achilles tendons using electron microscopy in rats
at PND30 treated with a very high dose of Ciproﬂoxacin 600mg/kg/
day for ﬁve days by oral gavage (Bae et al., 2006). Therefore,
watchful waiting of joint development in treated neonates seems
mandatory, even at low doses of Ciproﬂoxacin.
4.7. Liver toxicity
The liver has been identiﬁed as a target organ of Ciproﬂoxacin
toxicity in both animal and humans, as recently reviewed (Adikwu
and Brambaifa, 2012). We observed an increased number of he-
matopoiesis foci in treated mice in the 100 mg/kg/day group,
possibly due to increased immune response, as supported by the
moderate inﬂammatory inﬁltrates in connective tissues. The pre-
sent results extend previous results showing fetal toxicity of Cip-
roﬂoxacin in rats, with decreased fetal liver weight, and increased
degenerative cells in zone 11 and 111 of the fetus liver (Channa and
Janjua, 2003).
4.8. Juvenile animal studies
The present study was part of the TINN EU program that aims at
assessing the safety of Ciproﬂoxacin use in neonates, this drug
being included in the EMEA priority list for studies into off-patent
pediatric medicinal products. Preclinical and clinical results of the
TINN project will serve as a basis for a PUMA application. As pre-
viously noted, the importance of conducting preclinical safety
studies in developing mammals with special consideration for or-
gan systems that undergo signiﬁcant postnatal development has
been stressed by both Food and Drug Administration, and the Eu-
ropean Medical Agency (Soellner and Olejniczak, 2013). Despite
their limitations, juvenile animal studies are frequently requested
by regulatory agencies, for example in the frame of Pediatric
T. Bourgeois et al. / Regulatory Toxicology and Pharmacology 74 (2016) 161e169 169Investigation Plans (Baldrick, 2010). The TINN project aimed at
validating new tools to improve the sensitivity of pediatric pre-
clinical studies. The present study shows that the technological
limitations to conduct neurodevelopmental studies in newborn
rodents during the dosing period are being overcome.
5. Conclusion
This study was conducted to assess the possible adverse effects
of Ciproﬂoxacin on postnatal development in mice. We found that
subcutaneous administration of 100 mg/kg/day led to a moderate
toxicity mainly characterized by transient decrease in weight gain,
modest psychomotor and physiological effects during the dosing
period, and moderate impairments of joints and liver development.
However, no lasting effects were observed on vital functions, psy-
chomotor development, exploratory behavior, joint cartilage and
skeletal development at 10 and 30 mg/kg/day. Extrapolation from
mice to humans and even more from newborn mice to neonates
should be cautious, but according to the present study, Ciproﬂox-
acin is potentially toxic in neonates when used at therapeutic
doses. Thus, the present results plead for careful watching of
cardiorespiratory and motor development during and after treat-
ment with Ciproﬂoxacin in neonates, in addition to the standard
surveillance of arthrotoxicity.
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